Skip to content
DataLookout
Menu

IFM 2018-04NCT03606577

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 33 words Show 4 more changesShow less
    • Primary completion date changed from estimate of Feb 8, 2022 to Jul 18, 2022
    • Study completion pushed from Nov 8, 2027 to Apr 18, 2028
    • Study sites: 12 to 10
    • Publications: details revised at 2 of 2 entries
  2. Notable Primary completion date: Feb 8, 2021 to Feb 8, 2022
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 12 of 12 sites
    v6
  3. Notable Eligibility criteria expanded, about 7 words
    • Primary completion date: Feb 2, 2021 to Feb 8, 2021
    • Study completion date: Nov 2, 2027 to Nov 8, 2027
    • Site details revised at 10 of 12 sites
    v5
  4. Minor Study sites: 1 to 12v4
  5. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Feb 2, 2020 to Feb 2, 2021
    • Start date changed from estimate of Nov 2, 2018 to Jul 30, 2019
    • Study completion date: Nov 2, 2026 to Nov 2, 2027
    • Site details revised
  6. Minor Study title shortened, about 12 wordsv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of patients receiving the second Autologous Stem Cell Transplant
Timeframe: 15 months

Secondary (9)

Number of adverse events
Number of responses
Number of MRD
Number of death
Percentage of time to progression
Show 4 moreShow less
Number of patients having survival without progress
Percentage duration of response
Number of cells collected
percentage of value of biological prognostic factors

Arms and interventions

Carfilzomib, Daratumumab, Lenalidomide and DexaméthasoneExperimental

Drugs: Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone

Sites

10 sites in 1 country